Form 8-K - Current report:
SEC Accession No. 0001140361-23-048183
Filing Date
2023-10-13
Accepted
2023-10-13 16:15:43
Documents
12
Period of Report
2023-10-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K ef20012551_8k.htm   iXBRL 8-K 32084
  Complete submission text file 0001140361-23-048183.txt   172899

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atai-20231010.xsd EX-101.SCH 3856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20231010_lab.xml EX-101.LAB 23290
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20231010_pre.xml EX-101.PRE 16546
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20012551_8k_htm.xml XML 4213
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 231325243
SIC: 2834 Pharmaceutical Preparations